EA202091579A1 - Содержащие ганглиозид gm-3 наночастицы в качестве иммуномодуляторов - Google Patents
Содержащие ганглиозид gm-3 наночастицы в качестве иммуномодуляторовInfo
- Publication number
- EA202091579A1 EA202091579A1 EA202091579A EA202091579A EA202091579A1 EA 202091579 A1 EA202091579 A1 EA 202091579A1 EA 202091579 A EA202091579 A EA 202091579A EA 202091579 A EA202091579 A EA 202091579A EA 202091579 A1 EA202091579 A1 EA 202091579A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- pharmaceutical composition
- suppressor cells
- present
- patients
- Prior art date
Links
- 239000002955 immunomodulating agent Substances 0.000 title abstract 2
- 229940121354 immunomodulator Drugs 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 210000004479 myeloid suppressor cell Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- -1 GM3 ganglioside Chemical class 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/812—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Настоящее изобретение относится к фармацевтической композиции, активный ингредиент которой включает конъюгаты мембранных везикул Neisseria meningitidis и ганглиозида GM3 в соотношении конъюгации с избытком белков, имеет особые характеристики размера, поверхностного заряда и морфологии, связанные с системами наночастиц, которые придают ему полезные свойства в качестве иммуномодулятора, поскольку он индуцирует удобное и значительное уменьшение супрессорных клеток миелоидного происхождения, что влияет на ответ Т-лимфоцитов и на выживаемость пациентов с опухолями. Настоящее изобретение дополнительно относится к применению раскрытой фармацевтической композиции при лечении рака, в частности тех раковых заболеваний, где уровень супрессорных клеток миелоидного происхождения (MDSCs) являются высокими; а также к способу лечения указанной композицией больных раком и способу выбора тех, кто будет получать указанное лечение.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000173A CU20170173A7 (es) | 2017-12-27 | 2017-12-27 | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
| PCT/CU2018/050005 WO2019129313A1 (es) | 2017-12-27 | 2018-12-17 | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091579A1 true EA202091579A1 (ru) | 2020-09-17 |
Family
ID=65411690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091579A EA202091579A1 (ru) | 2017-12-27 | 2018-12-17 | Содержащие ганглиозид gm-3 наночастицы в качестве иммуномодуляторов |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11766462B2 (ru) |
| EP (1) | EP3733200A1 (ru) |
| JP (1) | JP2021507932A (ru) |
| KR (1) | KR20200104366A (ru) |
| CN (1) | CN111727052B (ru) |
| AR (1) | AR113981A1 (ru) |
| AU (1) | AU2018396991A1 (ru) |
| BR (1) | BR112020013036A2 (ru) |
| CA (1) | CA3087109A1 (ru) |
| CO (1) | CO2020008353A2 (ru) |
| CU (1) | CU20170173A7 (ru) |
| EA (1) | EA202091579A1 (ru) |
| MX (1) | MX2020006847A (ru) |
| SG (1) | SG11202006272PA (ru) |
| TW (1) | TWI721352B (ru) |
| WO (1) | WO2019129313A1 (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20170173A7 (es) | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0657175B1 (en) * | 1993-12-09 | 2005-03-02 | Centro de Inmunologia Molecular | Vaccine comprising human autologous epidermal growth factor and use thereof |
| CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
| US6149921A (en) * | 1993-12-29 | 2000-11-21 | Centro De Inmunologia Molecular | Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment |
| PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| CU23257A1 (es) * | 2003-02-27 | 2008-01-24 | Centro Inmunologia Molecular | COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA |
| CU23403A1 (es) * | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| GB0506001D0 (en) * | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Novel use |
| CU24070B1 (es) * | 2011-12-27 | 2015-01-29 | Ct De Inmunología Molecular | Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3) |
| CU24299B1 (es) * | 2013-08-02 | 2017-12-08 | Centro De Inmunología Molecular | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
| CU20170173A7 (es) | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
-
2017
- 2017-12-27 CU CU2017000173A patent/CU20170173A7/es unknown
-
2018
- 2018-12-17 KR KR1020207021766A patent/KR20200104366A/ko not_active Application Discontinuation
- 2018-12-17 EP EP18847186.6A patent/EP3733200A1/en active Pending
- 2018-12-17 CN CN201880089583.6A patent/CN111727052B/zh active Active
- 2018-12-17 MX MX2020006847A patent/MX2020006847A/es unknown
- 2018-12-17 US US16/957,597 patent/US11766462B2/en active Active
- 2018-12-17 EA EA202091579A patent/EA202091579A1/ru unknown
- 2018-12-17 AU AU2018396991A patent/AU2018396991A1/en active Pending
- 2018-12-17 BR BR112020013036-2A patent/BR112020013036A2/pt unknown
- 2018-12-17 CA CA3087109A patent/CA3087109A1/en active Pending
- 2018-12-17 JP JP2020536186A patent/JP2021507932A/ja active Pending
- 2018-12-17 WO PCT/CU2018/050005 patent/WO2019129313A1/es unknown
- 2018-12-17 SG SG11202006272PA patent/SG11202006272PA/en unknown
- 2018-12-19 AR ARP180103720A patent/AR113981A1/es unknown
- 2018-12-25 TW TW107146961A patent/TWI721352B/zh active
-
2020
- 2020-07-07 CO CONC2020/0008353A patent/CO2020008353A2/es unknown
-
2023
- 2023-08-17 US US18/235,157 patent/US20240033302A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3087109A1 (en) | 2019-07-04 |
| SG11202006272PA (en) | 2020-08-28 |
| AR113981A1 (es) | 2020-07-08 |
| CO2020008353A2 (es) | 2020-10-30 |
| US20200330527A1 (en) | 2020-10-22 |
| MX2020006847A (es) | 2020-08-24 |
| BR112020013036A2 (pt) | 2020-11-24 |
| CN111727052B (zh) | 2023-08-04 |
| AU2018396991A1 (en) | 2020-08-13 |
| EP3733200A1 (en) | 2020-11-04 |
| US11766462B2 (en) | 2023-09-26 |
| JP2021507932A (ja) | 2021-02-25 |
| WO2019129313A1 (es) | 2019-07-04 |
| US20240033302A1 (en) | 2024-02-01 |
| CN111727052A (zh) | 2020-09-29 |
| TW201938191A (zh) | 2019-10-01 |
| CU20170173A7 (es) | 2019-11-04 |
| KR20200104366A (ko) | 2020-09-03 |
| TWI721352B (zh) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005645A (es) | Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer. | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
| MA41520B2 (fr) | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers | |
| MX2021011242A (es) | Conjugados de vesícula extracelular y usos de estos. | |
| MX2023014093A (es) | Compuestos que interactuan con glicano y metodos de uso. | |
| MX2022015748A (es) | Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer. | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| EA201691079A1 (ru) | Комбинированная терапия для лечения онкологического заболевания | |
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| EA201690868A1 (ru) | Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга | |
| NZ591882A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers | |
| MX2019010601A (es) | Terapia de combinacion para tratar cancer. | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| MY196747A (en) | Cell injury inducing therapeutic drug for use in cancer therapy | |
| PH12021551036A1 (en) | Anti-liv1 immune cell cancer therapy | |
| EA201690680A1 (ru) | Комбинированное противоопухолевое лечение с применением миниклеток, загруженных лекарственным средством, нацеленных с использованием биспецифического лиганда, и интерферона-гамма | |
| RU2014141365A (ru) | Способ введения противоопухолевого агента | |
| RU2015152785A (ru) | Лечение злокачественной опухоли налтрексоном | |
| EA202091579A1 (ru) | Содержащие ганглиозид gm-3 наночастицы в качестве иммуномодуляторов | |
| EA202191323A1 (ru) | Применение 3-о-сульфамата 16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний | |
| MX369414B (es) | Peptido. |